Business context and reporting period
The supplied filing is Synta Pharmaceuticals Corp.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2015—not a filing identified as Madrigal Pharmaceuticals, Inc. Investors should verify the issuer and filing before relying on this summary. Synta was a clinical-stage oncology company developing ganetespib and its HDC drug-conjugate program; it reported no product revenue.
Financial results and position
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $14.4m | $16.2m | $47.0m | $52.6m |
| General and administrative | $3.0m | $3.2m | $10.3m | $11.5m |
| Operating loss | $(17.4)m | $(19.4)m | $(57.2)m | $(64.1)m |
| Net loss | $(17.6)m | $(20.0)m | $(58.1)m | $(65.8)m |
| Basic and diluted loss per share | $(0.13) | $(0.19) | $(0.46) | $(0.69) |
With no revenue, operating and net margins are not meaningful. Nine-month net loss narrowed by about 12%; weighted-average shares rose to 125.6m from 95.2m, so the improvement in loss per share also reflects dilution.
At September 30, cash and cash equivalents were $45.5m and marketable securities were $42.7m, totaling $88.3m, versus $97.7m at year-end 2014. Working capital was $59.6m. Nine-month operating cash use was $52.1m, compared with $59.7m in 2014. Investing activities provided $8.9m, primarily reflecting net sales and maturities of securities; financing provided $42.7m, including equity proceeds and $6.9m of loan repayments.
Total liabilities were $30.6m. Term loans totaled $6.9m, all classified as current at quarter-end; the GECC loan carried 9.75% interest, and the remaining Oxford equipment loan 13.35%. Total assets were $91.0m. No conventional profitability or positive operating cash flow was reported.
Material changes versus the prior comparable period
- Q3 R&D expense declined 11% year over year; nine-month R&D declined 11%. Lower ganetespib and early-stage program costs were partly offset by investment in STA-12-8666.
- Nine-month G&A expense fell 10%, partly because 2014 included about $2.0m of costs related to the former CEO’s separation.
- Nine-month net loss improved by $7.7m, while cash and marketable securities fell $9.4m from December 2014 despite equity financing.
- Shares outstanding increased from 109.1m at year-end 2014 to 137.8m at September 30, 2015. The April public offering generated $41.9m net; Q3 ATM sales generated $7.7m net.
Outlook, risks, and unusual items
After quarter-end, Synta announced termination of the Phase 3 GALAXY-2 ganetespib trial for futility: an interim review concluded the treatment was unlikely to significantly improve overall survival. The company said the combination was generally well tolerated. Synta planned to continue selected investigator-sponsored studies while reviewing ganetespib’s future and advancing its HDC pipeline; STA-12-8666 was in IND-enabling studies.
In November 2015, Synta committed to a restructuring reducing its workforce by about 45 positions, to approximately 33 employees. Estimated cash costs were $2.5m–$2.6m, mostly expected in Q4 2015; a potential equipment impairment charge had not yet been quantified. Management expected lower expenses after the trial termination and restructuring and projected the $88.3m of September 30 cash resources would fund operations at least through the first half of 2017, assuming no new financing or partnerships. This is a forward-looking estimate, not a guarantee.
The October 2015 Cowen ATM agreement permits up to $100m of share sales, with commissions up to 3%; no shares had been sold under it as of the filing. The company also cited potential need for additional funding, uncertain clinical and regulatory outcomes, and possible dilution or unfavorable partnership terms. As of November 4, 2015, its share price was $0.65 and had been below Nasdaq’s $1 minimum bid threshold for ten consecutive trading days, creating a potential delisting risk if the deficiency continued.
The filing reported no material legal proceedings and no material changes to previously disclosed contractual commitments. Management stated disclosure controls were effective and there were no material changes in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer: the provided filing names Synta Pharmaceuticals Corp., not Madrigal Pharmaceuticals, Inc.
- Review the GALAXY-2 termination and any subsequent decisions on ganetespib’s development.
- Assess cash runway against actual post-restructuring cash use, the estimated restructuring costs, and any unquantified asset impairment.
- Track financing and dilution, including any sales under the $100m Cowen ATM and the terms of future capital raises.
- Check subsequent Nasdaq listing status and developments in STA-12-8666, other HDC candidates, and ongoing investigator-sponsored trials.